Jakafi (ruxolitinib) Letter of Medical Necessity
Jakafi (ruxolitinib) requires confirmed hematologic diagnosis with cytogenetic/molecular workup and risk stratification. LMNs must include the diagnostic basis and risk score.
FDA-Approved Indications
- ● intermediate or high-risk myelofibrosis
- ● polycythemia vera (after hydroxyurea)
- ● acute and chronic graft-versus-host disease
- ● vitiligo (topical formulation)
Why Jakafi Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Diagnosis not confirmed by bone marrow biopsy
- 2. Risk score not documented
- 3. Hydroxyurea trial missing for PV
What to Include in a Jakafi Letter of Medical Necessity
Document diagnosis confirmation method (bone marrow biopsy, JAK2/CALR/MPL mutation status), DIPSS or DIPSS-Plus risk score, prior therapy outcomes, baseline labs, and clinical justification for ruxolitinib.
Key clinical evidence to cite:
- ✓ COMFORT-I and COMFORT-II for myelofibrosis
- ✓ RESPONSE for PV
- ✓ REACH-2 and REACH-3 for GVHD
Relevant guidelines:
- 📖 NCCN Myeloproliferative Neoplasms Guidelines
- 📖 ASH GVHD Guidelines
Jakafi Prior Authorization Criteria
Standard criteria across major US payers for Jakafi. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Hydroxyurea trial missing for PV
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Jakafi
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Jakafi Prior Authorization FAQ
Why was my Jakafi prior authorization denied?
The most common denial reasons for Jakafi are: Diagnosis not confirmed by bone marrow biopsy; Risk score not documented; Hydroxyurea trial missing for PV.
What should a Jakafi Letter of Medical Necessity include?
Document diagnosis confirmation method (bone marrow biopsy, JAK2/CALR/MPL mutation status), DIPSS or DIPSS-Plus risk score, prior therapy outcomes, baseline labs, and clinical justification for ruxolitinib.
Which payers cover Jakafi?
Jakafi is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part D, though formulary tier and prior authorization criteria vary.